A Double-Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD

CNS Neuroscience and Therapeutics

Volumn 17, Issue 5, 2011, Pages 305-310

  Yeh, Mary S L ^a   Mari, Jair Jesus ^a,b   Costa, Mariana Caddrobi Pupo ^a   Andreoli, Sergio Baxter ^a   Bressan, Rodrigo Affonseca ^a   Mello, Marcelo Feijó ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinician administered PTSD scale; Posttraumatic stress disorder; Randomized controlled clinical trial; Topiramate

Indexed keywords

PLACEBO; TOPIRAMATE;

ADULT; ARTICLE; BRAZIL; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EMOTION; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MALE; NIGHTMARE; OUTCOME ASSESSMENT; PARESTHESIA; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL ISOLATION; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT DURATION;

ADULT; AMBULATORY CARE; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 80053210825     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00188.x     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington DC: APA, 1980.
2. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:1048-1060.
3. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2006;25:CD 002795.
4. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Washington, DC: APA, 2004.
5. Post RM, Weiss SR, Smith M, Li H, McCann U. Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder. Ann N Y Acad Sci 1997;821:285-295.
6. Shank RP, Joseph FG, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl 1):S3-S9.
7. Wauquier A, Zhou S. Topiramate: A potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24:73-77.
8. Berlant JL. Antiepileptic treatment of posttraumatic stress disorder. Prim Psychiatry 2003;10:41-49.
9. Stephan JC. Corticotropin-releasing hormone (CRH) in psychiatry: From stress to psychopathology. Ann Med 2004;36:50-61.
10. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry 1993;34:18-25.
11. Sapolsky RM. Glucocorticoids, hippocampal damage and the glutamaterigoc synapse. Prog Brain Res 1990;86:13-23.
12. Zullino DF, Krenz S, Besson J. AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. J Clin Psychiatry 2003;64:219-220.
13. Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992; 49:624-629.
14. First M, Spitzer RL, Gibbon M, Williams JBW. The structured clinical interview for DSM-III-R personality disorders (SCID-II). Part I: Description. J Pers Disord 1995;9:83-91.
15. Andreoli SB, Ribeiro WS, Quintana MI, et al. Violence and post-traumatic stress disorder in Sao Paulo and Rio de Janeiro, Brazil: The protocol for an epidemiological and genetic survey. BMC Psychiatry 2009;9:34-42.
16. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995;8:75-90.
17. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
18. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, 1976.
19. Singer JM, Polero FZ, Rosa P. Parametric and nonparametric analyses of repeated ordinal categorical data. Biom J 2004;46:460-473.
20. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry 2002;63:15-20.
21. Berlant J. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004;4:24-30.
22. Akuchekian Sh, Amanat S. The comparison of topiramate and placebo in the treatment of posttraumatic stress disorder: A randomized, double-blind study. J Res Med Sciences 2004;5:240-244.
23. Tucker P, Trautmann RP, Wyatt DB, Thompson J, Wu SC, Capece JA, Rosenthal NR. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007;68:201-206.
24. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007;27:677-681.
25. Davidson JRT, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27:85-88.
26. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder: Randomized, double-blind study. BR J Psychiatry 1999;175:17-22.
27. Berlant JL. Topiramate as a therapy for chronic PTSD. Psychiatry 2006;3:40-45.